Novartis Looks To File Fabhalta By Year-End For C3G

The company presented positive Phase III data at the American Society of Nephrology meeting for the factor B inhibitor in C3G, a rare kidney disease with no approved treatments.

Novartis

Novartis AG is looking to add a third indication to the label of Fabhalta (iptacopan) on the back of Phase III data in C3 glomerulopathy (C3G), a disease that has no US Food and Drug Administration-approved treatments.

Novartis presented data on 26 October at the American Society of Nephrology (ASN) meeting from the APPEAR-C3G trial, which enrolled...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from Therapy Areas

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.